Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 85.03 M

Evolus, Inc. Cash and Short-Term Investments is USD 85.03 M for the quarter ending September 30, 2024, a 119.81% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Evolus, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 38.69 M, a -41.00% change year over year.
  • Evolus, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 65.57 M, a -39.17% change year over year.
  • Evolus, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 107.80 M, a -2.11% change year over year.
  • Evolus, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 110.12 M, a 48.76% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
Loading...
SV Wall Street
NasdaqGM: EOLS

Evolus, Inc.

CEO Mr. David Moatazedi
IPO Date Feb. 8, 2018
Location United States
Headquarters 520 Newport Center Drive
Employees 322
Sector Consumer Discretionary
Industries
Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 127.12

0.07%

ALKS

Alkermes plc

USD 31.53

-1.19%

PCRX

Pacira BioSciences, Inc.

USD 26.26

-3.06%

PBH

Prestige Consumer Healthcare Inc.

USD 87.35

14.78%

ANIP

ANI Pharmaceuticals, Inc.

USD 60.19

0.64%

PAHC

Phibro Animal Health Corporation

USD 24.58

9.88%

SUPN

Supernus Pharmaceuticals, Inc.

USD 38.85

-1.60%

IXHL

Incannex Healthcare Limited

USD 1.67

2.45%

COLL

Collegium Pharmaceutical, Inc.

USD 30.95

0.78%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 32.79

0.00%

PROC

Procaps Group S.A.

USD 1.59

0.00%

StockViz Staff

February 8, 2025

Any question? Send us an email